DIHEXA · DECODED
Dihexa
Decoded · Grey Market · Animal Data Only
BY THE NUMBERS
HOW IT WORKS
Proposed to act as an HGF/c-Met superagonist, activating hepatocyte growth factor signaling to promote synaptogenesis and cognitive enhancement. This is a working hypothesis, not an established mechanism. The founding paper by Rockenstein et al. (2012) was retracted in 2024. The 2014 Benoist et al. contextual learning study is valid but does not independently confirm the proposed HGF/c-Met mechanism.
WHERE IT CAME FROM
Dihexa (also designated PNB-0408) is a synthetic hexapeptide derived from angiotensin IV, a fragment of the renin-angiotensin system that regulates blood pressure and has central nervous system effects including memory and cognitive function. It was developed by researchers at Washington State University (primarily the Bhagat and McCoy groups) investigating whether angiotensin IV analogs could be developed into cognitive-enhancing therapeutics. The proposed mechanism is agonism of the HGF/c-Met signaling pathway: hepatocyte growth factor (HGF) binding its receptor c-Met promotes synapse formation, neuronal survival, and learning-related plasticity in the brain.
In 2012, a paper by Rockenstein and colleagues (which later became the primary citation driving Dihexa's grey market reputation) claimed that Dihexa was orders of magnitude more potent than brain-derived neurotrophic factor (BDNF) in synapse formation assays. This claim circulated widely in nootropics communities. That paper was retracted in 2024. A separate 2014 paper by Benoist et al. studying contextual learning in animal models remains valid and provides legitimate evidence of Dihexa's cognitive effects in rodents. The HGF/c-Met mechanism is a working hypothesis. It is proposed based on pharmacological data and is not a confirmed, independently replicated mechanism of action.
THE STUDIES
WHAT THE STUDIES SHOW
VALID EVIDENCE
- ▸Contextual learning improvement in rodent models (Benoist et al., 2014)
- ▸Angiotensin IV analog: pharmacological rationale is plausible
- ▸Animal behavioral effects consistent across some models
RETRACTED / UNCONFIRMED
- ▸Potency claim vs. BDNF: founding paper RETRACTED 2024
- ▸HGF/c-Met mechanism: working hypothesis, not established
- ▸Synaptogenesis assay data from Rockenstein: INVALID (retracted)
- ▸Do not cite the 2012 paper. It is not valid evidence.
UNKNOWN
- ▸Any human cognitive or neurological effect
- ▸Safety profile in humans at any dose
- ▸Effective dose range in humans
- ▸Whether animal behavioral effects translate to human cognition
SIDE EFFECTS
REPORTED (ANECDOTAL ONLY)
- ▸No controlled safety data from human studies
- ▸Some users report cognitive effects and mood changes
- ▸Anecdotal reports of restlessness or overstimulation
- ▸Data quality: user forums, not clinical research
NOTABLE / MONITOR FOR
- ▸HGF/c-Met pathway: theoretically could interact with inflammatory or oncogenic signaling
- ▸No toxicology data in humans at grey market doses
- ▸Grey market supply: purity, concentration, and identity unverified
- ▸PCAC Meeting #2 (before Feb 2027) is first formal regulatory review
REGULATORY STATUS
Dihexa has no regulatory approval anywhere in the world, including Russia, which separates it from Semax and Selank. It was on the FDA's Category 2 prohibited list and was removed from that prohibition on April 15, 2026. The PCAC is scheduled to review Dihexa at a second meeting before February 2027. That review will be the first formal regulatory assessment of whether Dihexa has a legitimate compounding pathway. Currently, it has no approved supply chain, no IND, no human trials, and a retracted founding study. It has the weakest regulatory standing of any nootropic in this list.
PROS & CONS
PROS
- +Animal behavioral evidence for cognitive effects exists (Benoist et al., 2014)
- +Angiotensin IV pharmacology provides a mechanistic rationale
- +HGF/c-Met pathway, if confirmed, would be a novel cognitive target
- +PCAC review before Feb 2027 may clarify regulatory path
CONS
- −Founding study RETRACTED in 2024. Primary evidence basis is gone.
- −HGF/c-Met mechanism is unconfirmed working hypothesis
- −Zero human clinical trials of any kind
- −No regulatory approval anywhere in the world
- −Grey market supply with no quality control
- −Weakest evidence base of any nootropic in this series
DAILY PEPTIDE VERDICT
RANKING
Dihexa's grey market reputation was built almost entirely on one number from one study: 'a million times more potent than BDNF.' That study was retracted in 2024. What remains is a 2014 animal behavioral study and a proposed mechanism that hasn't been independently confirmed. That is a thin evidence foundation for a compound being used for cognitive enhancement. The legitimate interest in HGF/c-Met signaling as a cognitive target is real. It's a pharmacologically interesting pathway. But interesting pathways without human evidence are what Phase 1 and Phase 2 trials are designed to test. Until controlled human data exists, Dihexa is an animal-tested hypothesis with a retracted origin story.
DISCLAIMER · EDUCATIONAL USE ONLY
This document is for educational and informational purposes only. Dihexa is sold as a research chemical and does not hold FDA approval for human use. Information here synthesizes publicly available research data and does not constitute medical advice.